NYSE$AMN

AMN Healthcare Services Inc. · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

AMN Healthcare reported modest revenue growth in the fourth quarter of 2025 but posted a GAAP net loss, while adjusted EBITDA declined year over year.

For Q4 2025, AMN Healthcare generated revenue of 748225000, up 2% year over year. The company reported a GAAP net loss of -7696000, or -0.20 per diluted share, while adjusted diluted EPS was 0.22. Adjusted EBITDA was 54483000 with a margin of 7.3%.

  • Revenue increased 2% year over year to 748225000.
  • GAAP net loss was -7696000 compared to a larger loss in the prior year.
  • Adjusted diluted EPS was 0.22 for the quarter.
  • Adjusted EBITDA totaled 54483000 with a 7.3% margin.

Headline financials

Total Revenue

$748M

Previous: $735M+1.8%
EPS (adj)

$0.22

Previous: $0.75-70.7%
Adjusted EBITDA

$54.5M

Previous: $75.1M-27.5%
Adjusted EBITDA Margin

7.3%

Previous: 10.2%-28.4%
Avg Travelers on Assignment

8.7K

Previous: 9.2K-5.3%
Days Filled

48.0K

Previous: 51.6K-7.0%
Revenue per Day Filled

$2.83K

Previous: $2.65K+7.1%
Leverage Ratio

3.3

Previous: 3+10.0%
Free Cash Flow

$75.6M

No prior period
Net Income

-$7.7M

Previous: -$188M+95.9%
Operating Income

$8.12M

Previous: -$203M+104.0%
Gross Profit

$195M

Previous: $219M-10.9%
Cash & Equivalents

$34M

No prior period
Total Assets

$2.09B

No prior period

Revenue & EPS history

AMN Healthcare · Revenue · Quarterly

$748M

Q4 2025+1.8%vs Q4 2024
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

AMN Healthcare · $748M total across 3 segments · Q4 2025

  • Nurse & Allied Solutions
    $491M
  • Physician & Leadership
    $170M
  • Technology & Workforce
    $88M

Forward guidance

For the first quarter of 2026, AMN expects consolidated revenue between 1225000000 and 1240000000 and adjusted EBITDA margin between 9.7% and 10.2%.

Tailwinds

  • Q1 2026 revenue expected between 1225000000 and 1240000000.
  • Adjusted EBITDA margin projected between 9.7% and 10.2%.
  • Nurse and Allied revenue expected to increase significantly year over year in Q1.
  • Labor disruption revenue estimated at approximately 600000000 in Q1.
  • Operating margin guidance between 5.9% and 6.5%.

Headwinds

  • Physician and Leadership revenue expected to decline 5-8% year over year in Q1.
  • Technology and Workforce revenue projected to decline 16-18% year over year in Q1.
  • Gross margin guidance of 23.5% to 24.0% implies compression versus Q4 levels.
  • SG&A projected at 14.5% to 15.0% of revenue in Q1.
  • Ongoing reimbursement and cost pressures in healthcare environment.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-0.0%

Avg return

Earnings day

-1.9%

Avg return

5 days after

-0.6%

Avg return

30 days after

52%

34 / 66 earnings

Positive

+29.2%

Q1 2026

Best reaction

-29.5%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+29.2%+38.5%+41.5%
Q4 2025+11.4%+15.8%+4.2%
Q3 2025-3.4%-10.0%-11.8%
Q2 2025+2.3%+10.2%+23.2%
Q1 2025+8.2%+7.1%+3.8%
Q4 2024+6.7%+0.5%-6.8%
Q3 2024-29.5%-36.7%-36.2%
Q2 2024-3.1%-11.9%-24.0%
Q1 2024-9.3%+3.4%-10.1%
Q4 2023-20.9%-25.5%-24.7%
Q3 2023-12.2%-17.7%-9.5%
Q2 2023-16.4%-16.6%-18.6%
Q1 2023+7.7%+10.3%+18.0%
Q4 2022-4.0%-2.3%-13.4%
Q3 2022-7.5%-0.4%+1.7%
Q2 2022+1.8%-1.7%-12.7%
Q1 2022-8.2%-10.6%-1.3%
Q4 2021+8.8%+5.3%+10.4%
Q3 2021-8.2%-1.4%+3.7%
Q2 2021+5.4%+3.8%+15.4%
Q1 2021+7.6%+10.3%+11.0%
Q4 2020+4.1%-0.7%+1.4%
Q3 2020-5.8%-7.0%-1.9%
Q2 2020+4.8%-4.5%-1.7%
Q1 2020-9.3%-12.1%+13.0%
Q4 2019+9.6%+5.6%+4.0%
Q3 2019-0.5%+2.1%+0.8%
Q2 2019+7.7%+11.4%+15.5%
Q1 2019+1.9%-0.4%-6.0%
Q4 2018-12.5%-14.7%-26.7%
Q3 2018+13.3%+11.6%+23.9%
Q2 2018-15.2%-10.4%-5.4%
Q1 2018-21.9%-21.6%-14.6%
Q4 2017+4.8%+4.8%+10.9%
Q3 2017-3.6%-1.6%+16.3%
Q2 2017+1.1%+6.9%+4.4%
Q1 2017-6.8%-6.2%-9.0%
Q4 2016+4.0%+7.9%+10.3%
Q3 2016-1.6%-2.7%-7.8%
Q2 2016-11.9%-13.8%-13.5%
Q1 2016+1.0%
Q4 2015+1.8%
Q3 2015+5.9%
Q2 2015+0.1%
Q1 2015-1.4%
Q4 2014+2.0%
Q3 2014-1.7%
Q2 2014+5.7%
Q1 2014+3.8%
Q4 2013+1.4%
Q4 2012+13.4%
Q3 2013+13.4%
Q2 2013+6.1%
Q1 2013-1.3%
Q3 2012+4.0%
Q2 2012+5.5%
Q1 2011+19.4%
Q1 2012+6.1%
Q4 2011-2.0%
Q4 2009-2.0%
Q3 2011-3.7%
Q3 2010-3.7%
Q4 2010-1.4%
Q2 2010-1.4%
Q2 2011-1.4%
Q1 2010-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro